availability of a monoclonal antibody against SMA should facilitate further purification and characterization of this agent. The techniques utilized in these studies provide a method for the production of additional monoclonal antibodies to this group of viruses and also should be useful for the study of other occult viral agents.
The Norwalk-like viruses are 27-to 32-nm round viruses that have been associated with outbreaks of acute gastroenteritis with high secondary attack rates. Several immunologically distinct agents have been described including the Norwalk agent (1), the Hawaii agent (2) , and the Snow Mountain agent (SMA) (3) . Radioimmunoassays and enzyme immunoassays (EIA) have been developed for the Norwalk agent (4-7), the SMA (7, 8) , and the Hawaii agent (unpublished data). The reagents used in these assays consist of sera and stool specimens from human volunteers or chimpanzees experimentally challenged with these viruses. The Norwalk agent has been established through the use of these assays as an important cause of gastroenteritis throughout the world, and serologic surveys have shown a high prevalence of Norwalk antibody in both developed and developing countries (9) . More limited studies with SMA have associated this agent with outbreaks of gastroenteritis in various areas of the continental United States (10) (11) (12) and have shown that >50% of adults who have been tested have serum antibody to this virus (7) .
These assays also have allowed a partial purification and characterization of the agents from the stools of experimentally infected volunteers. The Norwalk agent, when purified from diarrheal stool, contains a single structural protein of Mr 59,000 (13) . In addition, a Mr 30,000 protein that reacts specifically with human postinfection serum but is not associated with virion has been detected in the stools of individuals infected with the Norwalk agent and has been termed "soluble antigen" (13) . Similar results have been obtained with the SMA, which contains a single structural protein of Mr 62,000 when purified from the stools of volunteers and a soluble antigen that has not been further characterized (14) . The presence of a single structural protein of the above size is characteristic of caliciviruses among known animal viruses (15) , but definitive classification of the Norwalk and Snow Mountain agents awaits characterization of their genomes.
Because virus is shed briefly and in small amounts by ill individuals (16) and no practical animal model or in vitro culture system is available (17, 18) , more extensive characterization of these agents has not been performed. In addition, the limited amounts of available viral antigen have hindered previous attempts to generate animal hyperimmune sera or monoclonal antibodies to these viruses.
Recently, the technique of in vitro immunization has been developed for the production of monoclonal antibodies (19) . A major advantage of this technique is that much smaller amounts of antigen are required to generate an immune response. This technique has been used to produce monoclonal antibodies to scarce or highly conserved antigens such as calmodulin (20) , osteoclast-activating factor (21) , and hypothalamic growth hormone-releasing factor (22) . We now report the use of this technique to develop a monoclonal antibody to SMA and the use of this antibody in the further characterization of SMA virion and soluble antigen.
MATERIALS AND METHODS
Viruses and Cells. SMA used these in experiments was derived from experimentally infected volunteers, all of whom were ill and subsequently seroconverted to SMA by radioimmunoassay or EIA (3, 7, 8 (19) containing 40% (vol/vol) fetal calf serum was added, and the culture was continued for a total of 3-5 days. On days 3, 4, and 5, an aliquot of spleen cells was removed and fused with nonsecreting X63-Ag8.653 myeloma cells at a 5:1 spleen/myeloma cell ratio by using 40% polyethylene glycol (Mr 1000; Aldrich) and 5% dimethyl sulfoxide in DMEM. Fused cells were adjusted to 1 x 105 spleen cells per ml in HAT medium (100 ,M hypoxanthine/230 ,uM thymidine/0.4 ,M aminopterin in DMEM containing 20% fetal calf serum; Sigma) and plated at 100 ,ul per well in 96-well plates (Costar, Cambridge, MA). Hybridomas were screened by the screening assay described below, and the positive hybridoma (SM-4) was recloned by limiting dilution and injected intraperitoneally in BALB/c mice previously primed with pristane (Aldrich).
Screening EIA. Hybridoma supernatants were screened for antibody to SMA by using a "double-sandwich" assay. Acute and convalescent sera from a volunteer challenged with SMA were adsorbed to alternate wells of %-well polystyrene plates and then incubated with a crude stool homogenate containing SMA derived from a second volunteer. The wells were washed, and hybridoma supernatant was added, followed by addition of horseradish peroxidase (HRP)-labeled goat anti-mouse IgG (Kirkegaard and Perry, Gaithersburg, MD). Assays were developed with tetramethylbenzidine (TMB) (Aldrich) in which absorbance was read at 450 nm. Supernatants that produced an absorbance in wells coated with convalescent serum twice that in wells coated with acute serum (or a positive/negative ratio of 2)
were considered positive.
Antibody Characterization. Antibody subclass was determined by a commercial EIA assay (Chemicon International, El Segundo, CA) and NaDodSO4/polyacrylamide gel electrophoresis of culture supernatant biosynthetically labeled with [35S]methionine (New England Nuclear). Ascites fluid was purified by chromatography on a Sephacryl S-300 column (Pharmacia). Aliquots of purified antibody were biotinylated by reaction with biotin-N-hydroxysuccinimide ester (Pierce) for 4 hr at room temperature (25) .
Specificity of SM-4 for SMA. The reaction of SM-4 with various antigens was investigated in one of two formats. Biotinylated SM-4 was used directly as indicator in the double sandwich assay described above, and the reaction was developed with avidin-linked HRP (Vector Laboratories) and TMB. To test the ability to detect SMA, acute and convalescent sera from a volunteer challenged with SMA were used as "capture antibodies" (to bind antigen from stool specimens). For testing the reaction with the Norwalk and Hawaii agents, pre-and postinfection sera from volunteers challenged with Norwalk or Hawaii were used as capture antibodies. In the second type of test, SM-4 was used as the capture antibody. SM-4 or a control IgM monoclonal antibody was adsorbed at 1 kug per well, followed by antigen, biotin-labeled human convalescent antibody (Norwalk or SMA), avidin-HRP, and TMB. The control monoclonal IgM used in this test and subsequently was Liab Ia (Litton Diagnostics, Charleston, SC), a mouse IgM monoclonal antibody to the murine histocompatability I-region-associated (Ia) antigen. The IgM was purified by polyethylene glycol precipitation and exclusion chromatography. Antigens used in these tests included crude stool homogenates from volunteers challenged with Norwalk, Hawaii, or SMA; fractions of a sucrose velocity gradient containing SMA virion; and soluble antigen as described below. Samples giving an absorbance twice that of control wells (positive/negative ratio of 2) were considered positive. Crossreactivity with feline calicivirus and SA-11 rotavirus was tested by incubating biotin-labeled SM-4 with methanol-fixed infected and uninfected Fc3Tg and MalO4 cells, respectively.
The specificity of SM-4 for SMA was further investigated by blocking EIA (8) . Blocking assays were performed with human convalescent sera as the capture antibody, followed sequentially by antigen, the unlabeled antibody being tested, and finally by biotin-labeled second antibody, either human or monoclonal. Tests were developed with avidin-HRP and TMB. After subtraction of the values obtained from unblocked wells coated with acute serum, the results for each dilution were calculated as the percentage of absorbance obtained from the unblocked positive control wells (-0.7-1.0). The titer of each antibody was calculated as the greatest dilution blocking 40% of the value of the unblocked control. The unlabeled antibodies tested included human acute and convalescent sera from a volunteer experimentally infected with SMA and monoclonal antibodies SM-4 and LiAb Ia. Two antigen preparations were used in the blocking assays. "Virion" consisted of SMA virions purified from the stool of an experimentally challenged volunteer by Genetron extraction, pelleting, and sucrose gradient centrifugation. Soluble antigen was obtained from the supernatant remaining after pelleting the virus from a similar stool preparation, concentrated by ammonium sulfate precipitation, and dialyzed against phosphate-buffered saline (0.05 M PO(-/0.15 M NaCl, pH 7.4) for 16 hr at 4°C.
Radioimmunocapture Assay (RICA). SMA virions from another volunteer were purified as described above for in vitro immunization and labeled with "25I (Amersham) at a specific activity of 13.75 mCi/,ug ( To further investigate the specificity of SM-4 for SMA, SMA virions were pelleted from a stool homogenate containing SMA and applied to a 10-40% sucrose gradient. The fractions from this gradient were tested by EIA with biotinlabeled SM-4 or polyclonal human IgG as indicator antibody. These results are shown in Fig. 1 preparation was made by pelleting the virion from a stool containing SMA, followed by precipitation of the remaining supernatant with ammonium sulfate. The reactivity of human antibody and SM-4 with dilutions of the concentrated soluble antigen is shown in Fig. 2 . This preparation of soluble antigen was highly reactive in the standard antigen assay with biotin-labeled human anti-SMA IgG as indicator and had a titer of 1:512. However, when biotin-labeled SM-4 was used as indicator, there was no reaction even at an antigen dilution of 1:4.
To confirm the specificity of SM-4, we tested the ability of unlabeled SM-4 to block the attachment of labeled human postinfection IgG to purified virion prepared by sucrose gradient centrifugation or to concentrated soluble antigen prepared as described above. SM-4 blocked the binding of human IgG to SMA virion and had a titer of 4 x 1i-0 (Fig.  3) block at any dilution. As an additional control, human postinfection serum blocked at an 8-fold higher titer than did preinfection serum. In contrast, SM-4 did not block the binding of labeled postinfection human IgG to concentrated soluble antigen, although unlabeled human postinfection serum did (Fig. 4) . In an additional set of experiments (data not shown), human postinfection serum completely blocked binding of labeled SM-4 to a crude stool homogenate containing SMA.
RICA. To determine the specific SMA protein toward which SM-4 is directed, we tested the ability of SM-4 bound to polyvinyl chloride plates to capture radiolabeled SMA. Bound antigen was disrupted and eluted by incubation with NaDodSO4 sample buffer and analyzed by NaDodSO4/PAGE and autoradiography (Fig. 5) . Control wells contained either the control IgM monoclonal antibody LiAb Ia, human prechallenge serum, human postchallenge serum, or no antibody. The partially purified, labeled virion preparation used for this experiment is shown in lane 2 and contained highly labeled bands at Mr values of51,000,41,000, and 29,000 as well as less highly labeled bands at Mr 92,000 and Mr 62,000. Both SM-4 (lane 4) and human postinfection serum (lanes 6 protein, whereas the corresponding control wells did not. A highly labeled Mr 51,000 component was also present but at a much lower activity relative to input and showed no evidence of specific capture. A diffuse band in the range of Mr 29,000-30,000 was also seen in all wells and may have been slightly more dense in the wells containing postinfection serum or SM-4. The significance of this band is unclear because of binding in the control monoclonal antibody wells and in wells containing no antibody (not seen well in this exposure) despite extensive washing. Lack of sufficient viral antigen precluded further attempts to better define this band, and further studies will be required to determine if a minor viral protein or degradation product is present.
DISCUSSION
The anti-SMA monoclonal antibody described in this report, The limited data available suggests that the relative affinity of SM-4 and postinfection IgG for SMA virion were similar. The end-point titer of a stool containing primarily SMA virion by gradient analysis was similar when tested by monoclonal antibody and postinfection serum (data not shown), and the reactivity of purified virions at a single dilution was similar for both antibodies (Fig. 1) . In addition, the amount of radiolabeled SMA virion captured by comparable amounts of SM-4 and postinfection IgG were equivalent. Finally, SM-4 at low titer was able to block binding of labeled postinfection IgG to SMA virion. In contrast, SM-4 did not react with soluble antigen at any dilution and did not block the reaction of human convalescent serum with soluble antigen. Thus, soluble antigen does not contain the virion epitope recognized by SM-4. Seen in this light, the failure of SM-4 to react with some samples positive in the serum-based assay may be due in part to the presence of primarily soluble antigen in these samples. Samples containing primarily soluble antigen have been noted before for the Norwalk agent (13) , and we were unable to isolate virion from one of the SM-4-negative, human serum-positive samples (data not shown).
The in vitro immunization system used in this study has a number of advantages over in vivo immunization procedures, including more rapid generation of immune spleen cells and in vitro manipulation of cofactors of the immune response (19) . This technique is particularly useful when little in the way of purified antigen is available, as was the case with SMA. The amount of SMA antigen used in this immunization was not measured directly but was estimated by visualization on a silver-stained polyacrylamide gel to constitute -10-20 ng of the Mr 62,000 protein. However, similar preparations have failed to elicit an antibody response when injected into intact guinea pigs (H.P.M., unpublished data). The development of a system capable of generating an immune response to small quantities of viral antigen along with the recent development of efficient enzyme assays for these agents (5-7) should allow development of monoclonal antibodies to other Norwalk-like viruses. This system may also have application to the study of other occult viral agents that have not been cultivated in vitro.
In summary, this report describes the development of an IgM monoclonal antibody, SM-4, specific for the Mr 62,000 SMA structural protein and the use of this reagent to further characterize SMA. The development of monoclonal antibodies to this group of agents will facilitate their purification and characterization, as well as provide reagents for extensive diagnostic and seroepidemiologic studies.
